Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.kint.2015.11.015 http://scihub22266oqcxt.onion/10.1016/j.kint.2015.11.015 C4801696!4801696!26924047     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Kidney+Int 2016 ; 89 (4): 949-55 Nephropedia Template TP {{tp|p=26924047|t=2016. Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition |pdf=|usr=}}{{26924047}} gab.com Text Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition JO: Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=26924047 #FOAvip Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage renal disease. The molecular pathogenesis of ADPKD is not completely known and there is no approved therapy. To date, there is limited knowledge concerning the molecular consequences of specific disease-causing mutations. Here we show that the ADPKD missense variant TRPP2D511V greatly reduces TRPP2 protein stability, and that TRPP2D511V function can be rescued in vivo by small molecules targeting the TRPP2 degradation pathway. Expression of the TRPP2D511V protein was significantly reduced compared to wildtype TRPP2. Inhibition of lysosomal degradation of TRPP2D511V by the FDA-approved drug chloroquine strongly increased TRPP2 protein levels in vitro. The validation of these results in vivo requires appropriate animal models. However, there are currently no mouse models harboring human PKD2 missense mutations, and screening for chemical rescue of patient mutations in rodent models is time-consuming and expensive. Therefore, we developed a Drosophila melanogaster model expressing the ortholog of TRPP2D511V to test chemical rescue of mutant TRPP2 in vivo. Notably, chloroquine was sufficient to improve the phenotype of flies expressing mutant TRPP2. Thus, this proof-of-concept study highlights the potential of directed therapeutic approaches for ADPKD, and provides a rapid throughput experimental model to screen PKD2 patient mutations and small molecules in vivo. Twit Text FOAVip Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition ????Kidney Int http://www.kidney.de/pget.php?&tw=1&pmid=26924047 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26924047 #FOAvip English Wikipedia <ref>{{Cite pmid|26924047}}</ref> Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition #MMPMID26924047 Hofherr A; Wagner CJ; Watnick T; Köttgen M Kidney Int 2016[Apr]; 89 (4): 949-55 PMID26924047show ga Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage renal disease. The molecular pathogenesis of ADPKD is not completely known and there is no approved therapy. To date, there is limited knowledge concerning the molecular consequences of specific disease-causing mutations. Here we show that the ADPKD missense variant TRPP2D511V greatly reduces TRPP2 protein stability, and that TRPP2D511V function can be rescued in vivo by small molecules targeting the TRPP2 degradation pathway. Expression of the TRPP2D511V protein was significantly reduced compared to wildtype TRPP2. Inhibition of lysosomal degradation of TRPP2D511V by the FDA-approved drug chloroquine strongly increased TRPP2 protein levels in vitro. The validation of these results in vivo requires appropriate animal models. However, there are currently no mouse models harboring human PKD2 missense mutations, and screening for chemical rescue of patient mutations in rodent models is time-consuming and expensive. Therefore, we developed a Drosophila melanogaster model expressing the ortholog of TRPP2D511V to test chemical rescue of mutant TRPP2 in vivo. Notably, chloroquine was sufficient to improve the phenotype of flies expressing mutant TRPP2. Thus, this proof-of-concept study highlights the potential of directed therapeutic approaches for ADPKD, and provides a rapid throughput experimental model to screen PKD2 patient mutations and small molecules in vivo. äTargeted rescue of a polycystic kidney disease mutation by lysosomal i(epmc).pdf DeepDyve Pubget Overpricing